CO037 | PERFORMANCE OF A QUALITATIVE POINT-OF-CARE TEST IN PATIENTS EXPERIENCING ACUTE THROMBOEMBOLIC OR MAJOR BLEEDING EVENTS TREATED WITH DOACs: THE T-BLEEDOAC MULTICENTER PROSPECTIVE COHORT STUDY
Abstract
Background and Aims. Management of acute thromboembolic or hemorrhagic events occurring during treatment with direct oral anticoagulants (DOACs) is challenging. Point-of-care tests to detect DOAC levels have been developed, but their role in emergency situations is poorly defined. The aim of the study was to evaluate the performance of a urinary, qualitative, strip test in comparison to plasma measurement to detect clinically relevant DOAC levels in patients with acute thromboembolism or major bleeding (MB) while on treatment with these agents. Methods. Patients admitted to the Emergency Department for acute thromboembolism or MB while on treatment with full-dose DOA Cs were included in a multicenter, prospective, cohort study where urine and blood samples were collected within 60 minutes of each other. Performance of the DOAC dipstick (separate pads for factor Xa and thrombin inhibitor) to detect DOAC plasma levels ≥30 ng/mL was assessed. DOAC plasma levels were assessed by drug-calibrated chromogenic assays or diluted thrombin time. Results. Of 232 patients enrolled in the study, 189 were included in the analysis (43 were excluded as in 42 samples were collected beyond 60 minutes of each other, and 1 DOAC plasma level was unavailable), 61 were admitted for acute thromboembolic events, and 128 for MB. One-hundred-seventy-two patients were treated with an anti-Xa inhibitor (76 apixaban, 55 rivaroxaban, 41 edoxaban) and 17 with dabigatran. Creatinine clearance <30 ml/min was found in 22.2% of patients: 26.6% vs 13.1% (p=0.038) of those with index MB or thromboembolic event, respectively. In the overall study population, the diagnostic performance of the urinary DOAC dipstick was good (accuracy 89.9% and 97.9% for anti-Xa and anti-IIa pads, respectively). Similar findings were observed across subgroups: accuracy was 88.5% and 90.6% for anti-Xa pads and 100% and 96.9% for anti-IIa pads in the thromboembolic and MB populations, respectively (Table). Conclusions. The urinary DOAC dipstick showed a good performance in detecting clinically relevant DOAC exposure in patients with acute thrombotic or bleeding events, with a better profile for anti-IIa. Management studies are needed to assess the role of this test in clinical practice.
Related
- Family history of postpartum hemorrhage is a risk factor for postpartum hemorrhage after vaginal delivery: results from the French prospective multicenter Haemorrhages and Thromboembolic Venous Disease of the Postpartum cohort study
- Prognostic value of modified thrombelastometry for thromboembolic risk stratification in neurosurgical patients: protocol for a prospective, multicenter, observational study (TENS).
- Exploring the views of people experiencing homelessness regarding their health and housing support, and their perspectives on deteriorating health and end of life support: a qualitative analysis
- Low Prevalence of HIV-1 Antiretroviral Resistance Among Patients Experiencing Virological Failure on Dolutegravir-Based Regimens: A Prospective Cohort Study in Bunia, Democratic Republic of the Congo
- Risk factors for venous thromboembolic events at 90 days in hospitalized patients with advanced cancer receiving palliative care: a multicenter retrospective cohort study
BibTeX
@article{vedovati2026co037,
title = {{CO037 | PERFORMANCE OF A QUALITATIVE POINT-OF-CARE TEST IN PATIENTS EXPERIENCING ACUTE THROMBOEMBOLIC OR MAJOR BLEEDING EVENTS TREATED WITH DOACs: THE T-BLEEDOAC MULTICENTER PROSPECTIVE COHORT STUDY}},
author = {Maria Cristina Vedovati},
journal = {Bleeding, Thrombosis and Vascular Biology},
year = {2026},
month = oct,
url = {https://www.btvb.org/btvb/article/view/739},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - CO037 | PERFORMANCE OF A QUALITATIVE POINT-OF-CARE TEST IN PATIENTS EXPERIENCING ACUTE THROMBOEMBOLIC OR MAJOR BLEEDING EVENTS TREATED WITH DOACs: THE T-BLEEDOAC MULTICENTER PROSPECTIVE COHORT STUDY
AU - Maria Cristina Vedovati
PY - 2026
DA - 2026/10/26
JO - Bleeding, Thrombosis and Vascular Biology
UR - https://www.btvb.org/btvb/article/view/739
AB - Background and Aims. Management of acute thromboembolic or hemorrhagic events occurring during treatment with direct oral anticoagulants (DOACs) is challenging. Point-of-care tests to detect DOAC levels have been developed, but their role in emergency situations is poorly defined. The aim of the study was to evaluate the performance of a urinary, qualitative, strip test in comparison to plasma measurement to detect clinically relevant DOAC levels in patients with acute thromboembolism or major bleeding (MB) while on treatment with these agents. Methods. Patients admitted to the Emergency Department for acute thromboembolism or MB while on treatment with full-dose DOA Cs were included in a multicenter, prospective, cohort study where urine and blood samples were collected within 60 minutes of each other. Performance of the DOAC dipstick (separate pads for factor Xa and thrombin inhibitor) to detect DOAC plasma levels ≥30 ng/mL was assessed. DOAC plasma levels were assessed by drug-calibrated chromogenic assays or diluted thrombin time. Results. Of 232 patients enrolled in the study, 189 were included in the analysis (43 were excluded as in 42 samples were collected beyond 60 minutes of each other, and 1 DOAC plasma level was unavailable), 61 were admitted for acute thromboembolic events, and 128 for MB. One-hundred-seventy-two patients were treated with an anti-Xa inhibitor (76 apixaban, 55 rivaroxaban, 41 edoxaban) and 17 with dabigatran. Creatinine clearance <30 ml/min was found in 22.2% of patients: 26.6% vs 13.1% (p=0.038) of those with index MB or thromboembolic event, respectively. In the overall study population, the diagnostic performance of the urinary DOAC dipstick was good (accuracy 89.9% and 97.9% for anti-Xa and anti-IIa pads, respectively). Similar findings were observed across subgroups: accuracy was 88.5% and 90.6% for anti-Xa pads and 100% and 96.9% for anti-IIa pads in the thromboembolic and MB populations, respectively (Table). Conclusions. The urinary DOAC dipstick showed a good performance in detecting clinically relevant DOAC exposure in patients with acute thrombotic or bleeding events, with a better profile for anti-IIa. Management studies are needed to assess the role of this test in clinical practice.
SN - 2785-5309
ER -